Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4042-4051

  Zillhardt, Marion ^a   Park, Sun Mi ^b,c   Romero, Iris L ^a   Sawada, Kenjiro ^a   Montag, Anthony ^a   Krausz, Thomas ^a   Yamada, S Diane ^a   Peter, Marcus E ^b   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORETINIB; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIOID OVARY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; OMENTUM; OVARY CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANILIDES; ANIMALS; ANOIKIS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINOLINES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959215032     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3387     Document Type: Article

References (32)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
2. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177:1053-64.
3. Birchmeier C, Birchmeier W, Gherardi E, Woude GFV. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. (Pubitemid 37493640)
4. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS,, et al. Effect of a c-Met specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 2007;18:841-9.
5. Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P, et al. Overexpression of the MET/HGF receptor in ovarian cancer. Int J Cancer 1994;58:658-62.
6. Huntsman D, Resau JH, Klineberg E, Auersperg N. Comparison of cmet expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 1999;155:343-8. (Pubitemid 29370384)
7. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny HA, Salgia R, et al. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-80.
8. Shinomiya N, Gao C, Xie Q, Gustafson M, Waters D, Zhang Y, et al. RNA interference reveals that ligand-independent Met activity is required for tumor cell signaling and survival. Cancer Res 2004;64:7962-70. (Pubitemid 39446930)
9. Zillhardt M, Christensen J, Lengyel E. An orally available small molecule inhibitor of c-Met, PF-2341066, reduces tumor burden in a preclinical model of ovarian cancer metastasis. Neoplasia 2010;12:1-10.
10. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predicitive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39. (Pubitemid 37204044)
11. Qian F, Engst S, Yamaguchi K, Yu P, Won K, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK 1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69:8009-16.
12. Srinivasan R, Linehan WM, Vaishampayan U, Logan T, Shankar SM, Sherman LJ, et al. A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC) [Abstract]. J Clin Oncol 2009;27: Suppl 5103.
13. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study [Abstract]. J Clin Oncol 2009;27: Suppl 4502.
14. Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010;16:3507-16.
15. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
16. Jeffers M, Rong S, Woude GFV. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996;16:1115-25. (Pubitemid 26061683)
17. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp 1999;66:1-15. (Pubitemid 129639017)
18. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells. Int J Cancer 2007;121:1463-72. (Pubitemid 47328704)
19. Kenny HA, Kaur S, Coussens L, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118:1367-79. (Pubitemid 351500430)
20. Dinulescu D, Ince T, Quade B, Shafer S, Crowley D, Jacks T. Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarin cancer. Nature Med 2005;11:63-70. (Pubitemid 40215839)
21. Romero I, Gordon I, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu D, et al. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res 2009;2:792-9.
22. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?Nat Rev Cancer 2007;7:495-507.
23. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803-15. (Pubitemid 32458690)
24. Abbas T, Dutta A. P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
25. Podar K, Tonon G, Sattler M, Tai Y, LeGouill S, Yasui H, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 2006;103:19478-83. (Pubitemid 46026056)
26. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Prac Oncol 2008;5:194-204. (Pubitemid 351493679)
27. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-81.
28. Hov H, Holt RU, Ro TB, Fagerli U-M, Hjorth-Hansen H, Baykov V, et al. A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 2009;10:6686-94. (Pubitemid 39346566)
29. Beviglia L, Matsumoto K, Lin C-S, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997;74:301-9. (Pubitemid 27321800)
30. Tang M, Zhou HY, Yam JW, Wong AST. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 2010;12:128-38.
31. Wang R, Kobayashi R, Bishop JM. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc Natl Acad Sci U S A1996;93:8425-30.
32. Knudsen BS, Zhao P, Resau JH, Cottingham S, Gherardi E, Xu E, et al. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in pre-clinical and clinical settings. Appl Immunohistochem Mol Morphol 2009;17:57-67.